Evidence map›Paper›PMID 37241774›Full record

ArticleMolecules (Basel, Switzerland)2023

Hybrid Nanocomposites of Tenoxicam: Layered Double Hydroxides (LDHs) vs. Hydroxyapatite (HAP) Inorganic Carriers.

Lauretta Maggi, Valeria Friuli, Giovanna Bruni, Alessia Rinaldi, Marcella Bini

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Lauretta MaggiDepartment of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy.ORCID 0000-0002-1408-8846
Valeria FriuliDepartment of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy.ORCID 0000-0002-2975-4362
Giovanna BruniDepartment of Chemistry, University of Pavia, Viale Taramelli 16, 27100 Pavia, Italy.ORCID 0000-0003-1958-2998
Alessia RinaldiNanocarbon Laboratory, Department of Mathematical, Physics and Informatics Sciences, University of Parma, Parco Area delle Scienze 7/A, 43124 Parma, Italy.
Marcella BiniDepartment of Chemistry, University of Pavia, Viale Taramelli 16, 27100 Pavia, Italy.ORCID 0000-0001-7099-0650
University of Pavia · ITUniversity of Parma · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The search for effective systems to facilitate the release of poorly bioavailable drugs is a forefront topic for the pharmaceutical market. Materials constituted by inorganic matrices and drugs represent one of the latest research strategies in the development of new drug alternatives. Our aim was to obtain hybrid nanocomposites of Tenoxicam, an insoluble nonsteroidal anti-inflammatory drug, with both layered double hydroxides (LDHs) and hydroxyapatite (HAP). The physicochemical characterization on the base of X-ray powder diffraction, SEM/EDS, DSC and FT-IR measurements was useful to verify the possible hybrids formation. In both cases, the hybrids formed, but it seemed that the drug intercalation in LDH was low and, in fact, the hybrid was not effective in improving the pharmacokinetic properties of the drug alone. On the contrary, the HAP-Tenoxicam hybrid, compared to the drug alone and to a simple physical mixture, showed an excellent improvement in wettability and solubility and a very significant increase in the release rate in all the tested biorelevant fluids. It delivers the entire daily dose of 20 mg in about 10 min.

Indexed as

HydroxidesNanocompositesHydroxyapatitesPiroxicamSpectroscopy, Fourier Transform InfraredHydroxidesHydroxyapatitesPiroxicamtenoxicamdrug deliveryHAPin vitro dissolution studiesLDHstenoxicam

Identifiers

PMID37241774
PMCPMC10224359
OpenAlexW4378516294

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.